Linked are articles #1 & 2 in a series of many detailing individual treatment results from #TREATME survey. At a later date, a comprehensive overview & analysis of pertinent data will be shared.🧵
OVERALL CONDITION
Over 81% on SCIG (n = 11) & 72% on IVIG (n=29) reported their overall condition improved. Strikingly, >52% reported feeling moderately to much better w/ >27% of the 38 respondents feeling “much better.” This is significantly better than most other surveyed txs!
TIME TO IMPROVEMENT
Responses varied substantially. 9 out of 25 (36%) respondents reported it took just 1 to 2 rounds of therapy before starting to feel better, while on the other extreme, 8 out of 25 (32%) respondents reported that over 10 rounds of IgG were required.
DURATION OF BENEFIT
Respondents who improved were asked how long they have benefited from IgG. Over 80% reported benefits lasting at least 6 months, with over 50% enjoying benefits for over a year. Around half were still continuing therapy at time of completion of this survey.
TREATMENT DURATION IN THOSE WHO DID NOT BENEFIT
Did the 9 who reported no benefits receive sufficient rounds of treatment? Hard to know for sure, but three received just 1-2 IVIG treatments, while only two received over 10 treatments.
SYMPTOM REBOUND UPON DISCONTINUATION
13 of 13 reported that when they discontinued IgG therapy, at least a few of their symptoms returned. This is especially distressing considering how challenging it is to access and afford IgG treatments long-term.
EFFECTS ON SYMPTOMS
I asked those who reported benefits how many of their symptoms significantly improved with IgG. Impressively, 6 in 25 (24%) reported that “most/all” symptoms significantly improved‼️, while another 9 in 25 (36%) reported “quite a few.”
This is unique compared to most other surveyed treatments where the majority of respondents reported that only one or a few symptoms significantly improved. I will look into this more closely & comprehensively at a later date.
What about specific symptoms? Read on.
This chart shows the symptoms that received at least 20 ratings. Feeling of weakness improved in 80% (n=20) while “brain fog” (n=28), POTS (n=23), fatigue (n=34) & PEM (n=34) improved in 79%, 73%, 72% & 59%, respectively. Promising! All surveyed symptoms are reviewed in article.
Don't forget to check out article #1 linked above on nattokinase, LK & SP where I explore the most promising brands, differences between ME/CFS & Long COVID, rebound, and lots more.
If you'd like to support this volunteer project, you may donate here. ko-fi.com/lcpharmd
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#TREATME
Check out the charts for #longCOVID & #MECFS to see how enzymes like NK stacked up against aspirin, Plavix, DOACs (example: apixaban), and heparin. I won't do a deep dive until I gather more data & close the survey but wanted to share some data so far!🧵
Very Quick thoughts: 1) Oral anticoagulants alone looks subpar in #pwLC likely bc they only prevent clot formation & don't degrade existing microclots. Goal is to give body a break so it may clear clots on its own, but some may be too sick to achieve this.
1) cont..
Also note small sample size, so can't draw strong conclusions yet.
2) Many #pwLC may have hyperactivated platelets so it would stand to reason than antiplatelet meds would help. While just 38% reported aspirin ALONE helped, 60% benefited from dual antiplatelet therapy.
Reviewing preliminary data from the survey (n=1,750!), here are some early observations on a few treatments:
1) Both #pwLC and #pwME benefit remarkably similarly from LDN. Check out the almost identical survey results for overall benefit & number of symptoms improved.
2) People are more likely to benefit from CoQ10 at doses 200 mg or higher, but even then, their overall condition improves only slightly.
2) Both #pwME & #pwLC benefit from anticoagulants (more on this another time - very interesting stuff!).
3) There is a clear increase in benefit when adding on antiplatelets to anticoagulants, but aspirin alone does not help many (78/255).
4) Interestingly, HEPARIN may be more beneficial in both pwME & pwLC than direct oral anticoagulants.
TREAT ME covers 150+ medications & supplements. Treatments were selected based on published trials, case reports, other relevant studies, results of earlier surveys I’ve written, direct patient accounts (incl lots of feedback from many of YOU🥰), and my own pharmacist intuition.
The survey has been granted IRB exemption.👍
Furthermore, @OpenMedF will be reviewing a summary of the survey results as they gather info for prospective research studies🤩😍
PLEASE join this effort to investigate #ME & #LongCOVID treatments!
🚨When assessing cardiovascular risk, history of COVID should be considered a risk factor for cardiovascular disease.
Official treatment guidelines should be updated to account for frequent SARS-CoV-2 reinfections & Long COVID.🧵 jamanetwork.com/journals/jama/…
For example:
This atherosclerotic cardiovascular disease (ASCVD) risk calculator estimates the 10-year risk of ASCVD.
One problem: the tool does NOT consider history of COVID & thus likely underestimates risk in this enormous new population.
👇 tools.acc.org/ASCVD-Risk-Est…
The risk calculator is often used to help guide therapy decisions. For example, USPSTF determined that for primary ASCVD prevention, aspirin use has a small net benefit in those aged 40-59 with a ≥10% ten-year risk of ASCVD, but not in those age 60+.
👇 jamanetwork.com/journals/jama/…
Also included:
Treatment & dosing schedule that optimizes efficacy & avoids drug interactions
I also discuss:
Dosing for both adults AND kids
How to optimize absorption w/ low bioavailable supps
When/how to take
Drug interactions when applicable
Brands
How one might combine all 12 of the treatments covered if desired
in vitro vs in vivo concentrations & calculations
etc